“Combi-targeting” mitozolomide: Conferring novel signaling inhibitory properties to an abandoned DNA alkylating agent in the treatment of advanced prostate cancer-Reference-Cited by-同舟云学术

“Combi-targeting” mitozolomide: Conferring novel signaling inhibitory properties to an abandoned DNA alkylating agent in the treatment of advanced prostate cancer

Published:2012-01-30 Issue:12 Volume:72 Page:1273-1285
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Fang Youqiang,Qiu Qiyu,Domarkas Juozas,Larroque-Lombard Anne-Laure,Rao Suman,Rachid Zakaria,Gibbs Bernard F.,Gao Xin,Jean-Claude Bertrand J.

Publisher

Wiley

Subject

Urology,Oncology

Reference28 articles.

1. Cancer statistics, 2006;Jemal;CA Cancer J Clin,2006

2. Sequencing hormonal ablation and radiotherapy in prostate cancer: A molecular and therapeutic prespective (Review);Hill;Oncol Rep,2002

3. Recent progress in management of advanced prostate cancer;Kantoff;Oncology (Williston Park),2005

4. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: Experience of a single center;Zhang;Urol Int,2007

5. Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 (‘Iressa’) induces cell-cycle arrest and inhibits proliferation in prostate cancer cells;Sgambato;J Cell Physiol,2004

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expedient synthesis and anticancer evaluation of dual‐action 9‐anilinoacridine methyl triazene chimeras;Chemical Biology & Drug Design;2020-08-19

2. Subcellular distribution and mechanism of action of AL906, a novel and potent EGFR inhibitor rationally designed to be green fluorescent;Investigational New Drugs;2020-07-09

3. Design, synthesis and biological activity of novel molecules designed to target PARP and DNA;Bioorganic & Medicinal Chemistry Letters;2017-02

4. Potential Anticancer Mechanisms of a Novel EGFR/DNA-Targeting Combi-Molecule (JDF12) against DU145 Prostate Cancer Cells: An iTRAQ-Based Proteomic Analysis;BioMed Research International;2017

5. Advances in the development of hybrid anticancer drugs;Expert Opinion on Drug Discovery;2013-05-07